Renal Denervation + PVI for Atrial Fibrillation

(ERADICATE-AF Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Rochester

Disqualifiers: Heart failure, Paroxysmal AF, Renal issues, others

No Placebo Group

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

Pulmonary vein isolation (PVI) is the cornerstone of ablation for atrial fibrillation (AF). Increased cardiac sympathetic stimulation can facilitate AF and reduction can be accomplished by renal artery denervation (RDN). The recently completed randomized trial, ERADICATE-AF, convincingly demonstrated that RDN plus PVI resulted in a reduction in recurrent incident AF for uncontrolled hypertensives. This is a randomized controlled pilot trial, "To Evaluate Renal Artery Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation" (ERADICATE-AF II) to test if RDN plus PVI enhances long-term efficacy vs PVI for persistent AF patients with controlled or without hypertension using implantable loop recordings.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Renal Denervation + PVI for Atrial Fibrillation?

Research shows that Pulmonary Vein Isolation (PVI) is a key part of treating atrial fibrillation (AF) and is recommended for patients with different types of AF. While the benefit of adding other techniques to PVI is unclear, PVI itself is recognized as a potentially curative treatment for AF. ^{1 2 3 4 5}

Is Renal Denervation + PVI for Atrial Fibrillation safe?

Pulmonary vein isolation (PVI), a key part of the treatment, is generally safe with severe complications occurring in 1-3% of patients. This suggests that while the procedure is mostly safe, there is a small risk of serious complications. ^{1 3 5 6 7}

How is the treatment Renal Denervation + PVI for Atrial Fibrillation different from other treatments?

Renal Denervation + PVI for Atrial Fibrillation is unique because it combines renal denervation, which targets nerves in the kidneys to help control blood pressure, with pulmonary vein isolation (PVI), a procedure that isolates the pulmonary veins to prevent erratic electrical signals in the heart. This combination aims to enhance the effectiveness of treating atrial fibrillation by addressing both heart rhythm and blood pressure issues. ^{1 3 4 8 9}

Eligibility Criteria

This trial is for adults over 18 with symptomatic persistent atrial fibrillation, which lasts more than 7 days but less than a year. Participants can either have no history of hypertension or controlled hypertension. They must be eligible for PVI, have renal arteries suitable for denervation, and agree to heart monitoring and follow-up requirements.

Inclusion Criteria

My blood pressure is under control, either naturally or with medication.

I am older than 18 years.

I have had atrial fibrillation symptoms for more than 7 days but less than a year.

Exclusion Criteria

I've had a procedure on my kidney arteries that prevents me from getting ablation treatment.

I have had atrial fibrillation that comes and goes or has lasted for more than a year.

I have had a procedure to correct an irregular heartbeat.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo pulmonary vein isolation (PVI) and may receive additional renal artery denervation (RDN)

Immediate procedure

1 visit (in-person)

Follow-up

Participants are monitored for safety, AF burden, and other clinical outcomes

12 months

Regular visits (in-person and virtual) at 0, 1, 3, 6, and 12 months

Long-term Follow-up

Participants are monitored for long-term outcomes such as AF recurrence and quality of life

Beyond 12 months

Treatment Details

Interventions

• Catheter Ablation (Procedure)
• Renal Artery Denervation (Procedure)

Trial Overview The study is testing if adding renal artery denervation (RDN) to the standard catheter ablation treatment called pulmonary vein isolation (PVI) improves outcomes in patients with persistent atrial fibrillation. It's a randomized pilot trial where some participants will receive both treatments while others only PVI.

Participant Groups

Group I: Pulmonary vein isolation + renal artery denervation Experimental Treatment 2 Interventions

After completion of the standard PVI, radiofrequency ablation of bilateral renal arteries

Group II: Pulmonary vein isolation Active Control 1 Intervention

Electrical isolation by cryoballoon of all pulmonary veins

Catheter Ablation is already approved in European Union, United States, Canada for the following indications:

🇪🇺 Approved in European Union as Pulmonary Vein Isolation (PVI) for:

• Symptomatic paroxysmal or persistent atrial fibrillation
• Heart failure with reduced left ventricular fraction

🇺🇸 Approved in United States as Pulmonary Vein Isolation (PVI) for:

• Symptomatic paroxysmal or persistent atrial fibrillation
• Heart failure with reduced left ventricular fraction

🇨🇦 Approved in Canada as Pulmonary Vein Isolation (PVI) for:

• Symptomatic paroxysmal or persistent atrial fibrillation
• Heart failure with reduced left ventricular fraction

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Rochester Short Hills, NJ

Who Is Running the Clinical Trial?

University of Rochester Lead Sponsor

National Heart, Lung, and Blood Institute (NHLBI) Collaborator

References

1. Netherlands pubmed.ncbi.nlm.nih.gov

Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis. [2021] Pulmonary vein isolation (PVI) forms the basis of catheter ablation strategies for atrial fibrillation (AF). Ablation of additional sites has been used to increase the efficacy of ablation procedures in restoring and maintaining normal sinus rhythm.

2. United States pubmed.ncbi.nlm.nih.gov

Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and nonparoxysmal atrial fibrillation: A meta-analysis. [2021] Pulmonary vein isolation (PVI) is recognized as a potentially curative treatment for atrial fibrillation (AF). Ablation of complex fractionated atrial electrograms (CFAEs) in addition to PVI has been advocated as a means to improve procedural outcomes, but the benefit remains unclear.

3. United States pubmed.ncbi.nlm.nih.gov

Initial results of using a novel irrigated multielectrode mapping and ablation catheter for pulmonary vein isolation. [2016] Pulmonary vein isolation (PVI) as a cornerstone for catheter ablation of atrial fibrillation (AF) remains a complex and time-consuming procedure.

4. United States pubmed.ncbi.nlm.nih.gov

Pulmonary vein isolation cryoablation for patients with persistent and long-standing persistent atrial fibrillation: Clinical outcomes from the real-world multicenter observational project. [2018] Pulmonary vein isolation (PVI) is a cornerstone ablation strategy in the management of patients with atrial fibrillation (AF). Consensus guidelines and statements recommend PVI during the index catheter ablation procedure in patients with paroxysmal and persistent AF.

5. United States pubmed.ncbi.nlm.nih.gov

Cryoballoon ablation of pulmonary veins for persistent atrial fibrillation: Results from the multicenter STOP Persistent AF trial. [2021] Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation to treat patients with symptomatic drug-refractory atrial fibrillation (AF).

6. Ireland pubmed.ncbi.nlm.nih.gov

A new circular mapping-guided approach for endoscopic laser balloon pulmonary vein isolation. [2020] Pulmonary vein isolation (PVI) for atrial fibrillation (AF) is performed with the endoscopically assisted laser balloon ablation system (EAS). We hypothesized that placement of a circular mapping catheter (CMC) in the pulmonary vein (PV) distal to the laser balloon during ablation is feasible and safe.

7. England pubmed.ncbi.nlm.nih.gov

Complications in pulmonary vein isolation in the Netherlands Heart Registration differ with sex and ablation technique. [2021] Pulmonary vein isolation (PVI) has become a cornerstone of the invasive treatment of atrial fibrillation. Severe complications are reported in 1-3% of patients. This study aims to compare complications and follow-up outcome of PVI in patients with atrial fibrillation.

8. England pubmed.ncbi.nlm.nih.gov

Duty-cycled multi-electrode radiofrequency vs. conventional irrigated point-by-point radiofrequency ablation for recurrent atrial fibrillation: comparative 3-year data. [2022] Pulmonary vein isolation (PVI) is an accepted treatment to relieve symptoms in patients with atrial fibrillation (AF). We studied 3 year outcome after PVI guided by duty-cycled multi-electrode radiofrequency (RF) ablation (pulmonary vein ablation catheter, PVAC) and provided comparative data to outcome after conventional PVI (CPVI) using mapping with irrigated, point-per-point RF ablation.

9. Netherlands pubmed.ncbi.nlm.nih.gov

Innovations in atrial fibrillation ablation. [2023] Catheter-based ablation to perform pulmonary vein isolation (PVI) has established itself as a mainstay in the rhythm control strategy of atrial fibrillation. This review article aims to provide an overview of recent advances in atrial fibrillation ablation technology.